Literature DB >> 22044070

A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.

Kirsi Tamminen1, Leena Huhti, Tiia Koho, Suvi Lappalainen, Vesa P Hytönen, Timo Vesikari, Vesna Blazevic.   

Abstract

Norovirus (NoV) -derived virus-like particles (VLPs) resemble empty shells of the virus and NoV P-particles contain only protruding domains of the NoV capsid. Both NoV-derived subviral particles show similar functionality and antigenicity in vitro and are considered to be potential vaccine candidates against NoV gastroenteritis. BALB/c mice were immunized with baculovirus-produced GII-4 VLPs or the corresponding Escherichia coli-produced P-particles by the intramuscular or intradermal route and the NoV-specific antibody and T-cell immune responses were compared. Elevated antibody levels were induced with a single VLP immunization, whereas P-particle immunization required a boost. High avidity antibodies were raised only by VLP immunization. VLP immunization resulted in a balanced T helper type 1/type 2 immune response whereas P-particles induced a T helper type 2-biased response. Only VLP immunization primed T cells for interferon-γ production. Most importantly, cross-reactive B and T cells were induced solely by VLP immunization. In addition, VLP antiserum blocked the binding of heterotypic VLPs to human histo-blood group antigen receptor and saliva. The findings in this study are relevant for the development of NoV vaccines.
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22044070      PMCID: PMC3246655          DOI: 10.1111/j.1365-2567.2011.03516.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Laboratory efforts to cultivate noroviruses.

Authors:  Erwin Duizer; Kellogg J Schwab; Frederick H Neill; Robert L Atmar; Marion P G Koopmans; Mary K Estes
Journal:  J Gen Virol       Date:  2004-01       Impact factor: 3.891

2.  Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein.

Authors:  X Jiang; M Wang; D Y Graham; M K Estes
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 3.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

4.  E. coli-expressed recombinant norovirus capsid proteins maintain authentic antigenicity and receptor binding capability.

Authors:  Ming Tan; Weiming Zhong; Dan Song; Scott Thornton; Xi Jiang
Journal:  J Med Virol       Date:  2004-12       Impact factor: 2.327

5.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

Authors:  Samer S El-Kamary; Marcela F Pasetti; Paul M Mendelman; Sharon E Frey; David I Bernstein; John J Treanor; Jennifer Ferreira; Wilbur H Chen; Richard Sublett; Charles Richardson; Robert F Bargatze; Marcelo B Sztein; Carol O Tacket
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

Review 6.  Antibody affinity and protection in virus infections.

Authors:  A A Salmi
Journal:  Curr Opin Immunol       Date:  1991-08       Impact factor: 7.486

7.  Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo.

Authors:  P M Taylor; B A Askonas
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

8.  The role of antibody concentration and avidity in antiviral protection.

Authors:  M F Bachmann; U Kalinke; A Althage; G Freer; C Burkhart; H Roost; M Aguet; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

Review 9.  Lymphokine control of in vivo immunoglobulin isotype selection.

Authors:  F D Finkelman; J Holmes; I M Katona; J F Urban; M P Beckmann; L S Park; K A Schooley; R L Coffman; T R Mosmann; W E Paul
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

10.  Identification of a T-helper cell epitope on the rotavirus VP6 protein.

Authors:  D M Baños; S Lopez; C F Arias; F R Esquivel
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

View more
  32 in total

1.  Affinities of human histo-blood group antigens for norovirus capsid protein complexes.

Authors:  Ling Han; Elena N Kitova; Ming Tan; Xi Jiang; Benjamin Pluvinage; Alisdair B Boraston; John S Klassen
Journal:  Glycobiology       Date:  2014-10-01       Impact factor: 4.313

2.  The formation of P particle increased immunogenicity of norovirus P protein.

Authors:  Ming Tan; Xi Jiang
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

3.  Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Hanni Uusi-Kerttula; Timo Vesikari; Vesna Blazevic
Journal:  Clin Vaccine Immunol       Date:  2015-04-22

Review 4.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

5.  Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice.

Authors:  Zhong-Hua Deng; Ye-Xia Hao; Li-Hong Yao; Zhi-Ping Xie; Han-Chun Gao; Le-Yun Xie; Li-li Zhong; Bing Zhang; You-De Cao; Zhao-Jun Duan
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

Review 6.  Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Authors:  Ming Tan; Xi Jiang
Journal:  Nanomedicine (Lond)       Date:  2012-06       Impact factor: 5.307

7.  Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.

Authors:  Shin-Hee Kim; Shun Chen; Xi Jiang; Kim Y Green; Siba K Samal
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

8.  Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.

Authors:  Jacob Kocher; Tammy Bui; Ernawati Giri-Rachman; Ke Wen; Guohua Li; Xingdong Yang; Fangning Liu; Ming Tan; Ming Xia; Weiming Zhong; Xi Jiang; Lijuan Yuan
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

9.  The state of norovirus vaccines.

Authors:  Kari Debbink; Lisa C Lindesmith; Ralph S Baric
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

10.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.